BioLig

Our mission goes beyond simple in silico predictions as we are aware of biology complexity. We intersect both knowledges in a way to gain deeper knowledge and maximum effort in tackling diseases.

Activities

⇒design of small peptides with high affinity for custom proteins (peptido-therapeutics)

⇒small molecule virtual screening (drug repurposing or bioactive compound identification)

⇒identification of regions of protein-protein or protein-ligand interactions

⇒design of prodrugs activated by the tumour micro-environment

⇒prediction of phenotypes associated with protein mutations

⇒accurate identification of substrates of Protein Kinase A (PKA)

design of bioactive peptides

small molecule docking

mutation phenotype prediction

Our deep knowledge on protein-protein interactions enhances the discovery and design of novel small molecule effectors.
We can produce specific modulators of proteins or protein complexes to contrast diseases.
We support the design and development of new drugs and find new uses for existing ones.
We actively aid in the interpretation of experimental results to save time and costs of experiments and accelerate the publication of cutting-edge research.
By strategic design, Biolig does not pursue its own clinical pipeline, instead it is our vision to be the partner that fosters the potential of academic and non-profit institutions, pharmaceuticals, and biotechs.

Info & Quotes

We can carry out the tasks listed below and also assist in writing down the discovered concepts supported by graphics and artworks for publication in scientific journals. Time of execution will be arranged and based on individual projects and the actual working load of our resources. We will do a preliminary and cost-free analysis of feasibility prior to any agreement. For any question, please contact us at info@biolig.com

projects

task

main focus

status

effectors

design

therapeutics

busy

docking

prediction

therapeutics

open